Cemiplimab + Cetuximab
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Head and Neck Squamous Cell Carcinoma
Conditions
Head and Neck Squamous Cell Carcinoma
Trial Timeline
Feb 26, 2025 → Mar 1, 2028
NCT ID
NCT06855212About Cemiplimab + Cetuximab
Cemiplimab + Cetuximab is a phase 2 stage product being developed by Eli Lilly for Head and Neck Squamous Cell Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06855212. Target conditions include Head and Neck Squamous Cell Carcinoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06855212 | Phase 2 | Recruiting |
Competing Products
20 competing products in Head and Neck Squamous Cell Carcinoma